Welcome to our dedicated page for Miromatrix Medical news (Ticker: MIRO), a resource for investors and traders seeking the latest updates and insights on Miromatrix Medical stock.
Miromatrix Medical Inc. (symbol: MIRO) is an innovative life sciences company focused on developing bioengineered organs for transplantation. The company leverages its proprietary technology to decellularize organs and tissues from both animal and human sources, creating a platform for producing fully transplantable human organs. This cutting-edge technology aims to address the critical shortage of donor organs, potentially saving and improving countless lives.
Miromatrix has garnered significant recognition for its pioneering work. The company's CEO, Dr. Jeff Ross, recently presented their advancements in kidney bioengineering at the American Transplant Congress (ATC), where they received the prestigious Best in Congress acknowledgment. Additionally, Miromatrix's Medical Director, Dr. Jack Lake, was honored with the American Society of Transplantation's 2023 Lifetime Achievement Award, the Society's highest honor, for his outstanding contributions to the field of transplantation.
The company's current focus is on the development of human livers and kidneys, utilizing its perfusion technology platform. This platform is designed to efficiently scale the bioengineering process, making it feasible to produce a larger number of transplantable organs. Miromatrix is actively involved in various research initiatives and collaborates with leading scientists such as David Lo to advance their technology further.
Financially, Miromatrix recently reported their second-quarter 2023 results, showcasing their progress and strategic direction. They continue to engage with investors and the media through scheduled presentations at significant events such as the ARM Tissue and Engineering and Therapeutics Workshop and the H.C. Wainwright Annual Global Investment Conference.
For the latest updates and detailed information on Miromatrix Medical Inc., including their recent achievements and ongoing projects, visit their official website at miromatrix.com.
Miromatrix Medical Inc. (NASDAQ: MIRO) announced the expansion of its board with the appointments of Lisa Wipperman Heine and William P. Burke. Heine, with over 25 years of leadership in life sciences, aims to address the transplant shortage through innovative solutions. Burke, former CFO at Haemonetics, brings experience in growth strategies and acquisitions. CEO Jeff Ross expressed confidence in their abilities to advance the company’s mission of bioengineering transplantable organs, primarily focusing on human livers and kidneys.
Miromatrix Medical Inc. (NASDAQ: MIRO) has submitted a pre-IND request to the FDA for its External Liver Assist Product aimed at treating acute liver failure. This step aims to facilitate the Phase I IND submission and initiate human clinical trials in the second half of 2022. Miromatrix's prior large animal studies displayed successful transplantation of bioengineered livers, with favorable early results in hepatic health and function. Approximately 80,000 people in the U.S. suffer from liver failure annually, underscoring the urgent need for innovative solutions.
Miromatrix Medical Inc. (NASDAQ: MIRO) reported its Q3 2021 financial results, highlighting significant advancements in bioengineering transplantable organs. Key achievements included raising approximately $49 million through an IPO and hiring Dr. John Barry as the new VP of Research and Development. The company successfully transplanted a bioengineered organ in a large animal and is preparing for a 2022 FDA IND submission for its Phase I Liver Assist Trial. Despite a revenue of $10,000 and a net loss of $5.1 million, cash reserves stood strong at $62.1 million.
Miromatrix Medical Inc. (NASDAQ: MIRO) will report its third quarter 2021 financial results on November 15, 2021, after market close. A conference call will follow at 3:30 PM CT to discuss these results. Miromatrix specializes in bioengineering fully transplantable organs, focusing on addressing the shortage of human organs. The company is particularly invested in developing human livers and kidneys using its proprietary perfusion technology. Interested parties can participate in the conference call by dialing the provided numbers or joining the live webcast on Miromatrix's investor relations page.
Miromatrix Medical Inc. (NASDAQ: MIRO) announced a significant milestone, successfully completing the first heterotopic implant of a bioengineered liver transplant in a large animal model. Conducted in collaboration with experts at Mayo Clinic, the study involved five pigs, three of which received the transplant. Results published in Nature Communications Biology show sustained blood perfusion and detectable liver function post-transplantation, addressing critical challenges in tissue engineering. Miromatrix is now targeting human clinical trials in the second half of 2022, aiming to reduce the organ transplant waitlist.
Miromatrix Medical Inc. (NASDAQ: MIRO) has been added to the Russell Microcap® Index, effective September 20, 2021. This inclusion aims to enhance its visibility and investor exposure as the company develops bioengineered organs. CEO Jeff Ross expressed optimism regarding the timing, noting the upcoming submission of an IND for a Phase I Liver Assist Trial in the first half of 2022. The Russell Microcap Index comprises the smallest securities from the Russell 2000® Index and is crucial for investors, with approximately $9 trillion in assets benchmarked to these indexes.
Miromatrix Medical Inc. (NASDAQ: MIRO) has appointed Dr. John Barry as the new Vice President of Research and Development. Dr. Barry will oversee the development of the company's transplantable liver and kidney programs, including a bioengineered liver for external applications. This follows the company’s plans for its first human study using a bioengineered liver scheduled for late 2022. Miromatrix aims to address the organ transplant shortage, with 114,000 individuals currently on the waiting list.
Miromatrix Medical (NASDAQ: MIRO), a biotechnology firm, announced significant funding from a Series C financing round led by Baxter, CareDx, and DaVita. The raised capital will expedite clinical trials for their bioengineered organ technology, specifically targeting liver and kidney programs. Miromatrix aims to launch a trial for its External Liver Assist Product in late 2022, addressing the critical shortage of transplantable organs in the U.S., where over 114,000 people await organ transplants.
Miromatrix Medical Inc. (Nasdaq: MIRO) announced the closing of its initial public offering (IPO) on June 28, 2021, selling 5,520,000 shares at $9.00 each, including an additional 720,000 shares purchased by underwriters. The company raised approximately $49.7 million in gross proceeds, aimed at advancing its innovative technology for bioengineering transplantable human organs, focusing on livers and kidneys. This offering was facilitated by Craig-Hallum Capital Group as the managing underwriter.
Miromatrix Medical Inc. (Nasdaq: MIRO) has priced its initial public offering (IPO) of 4,800,000 shares at $9.00 per share. The offering aims to raise approximately $43.2 million before underwriting fees. Additionally, the underwriter has a 30-day option to purchase 720,000 additional shares. Trading is set to commence on June 24, 2021, with the offering expected to close by June 28, 2021. The IPO will be managed by Craig-Hallum Capital Group.
FAQ
What is the market cap of Miromatrix Medical (MIRO)?
What does Miromatrix Medical Inc. specialize in?
What recent recognition has Miromatrix received?
What are Miromatrix's primary focus areas?
What technology does Miromatrix use for bioengineering organs?
How is Miromatrix addressing the shortage of donor organs?
Who are some key figures in Miromatrix?
What events has Miromatrix recently participated in?
Where can I find more information about Miromatrix?
What recent financial results has Miromatrix reported?
Who can I contact for investor relations at Miromatrix?
